|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.00 CNY | +0.29% |
|
+3.72% | +26.98% |
| 07-09 | Gan & Lee Pharmaceuticals sees H1 net profit up 100.7-114.1% Y/Y | RE |
| 07-08 | Gan & Lee Pharmaceuticals' Insulin Aspart Receives Approval in Argentina | CI |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
Medical Device Research and Development | ||||||||
Development, Production and Sales of Insulin and Related Products | 3.36B | 3.61B | 1.71B | 2.61B | 3.05B | |||
Total Assets | 9.51B | 10.85B | 10.61B | 11.72B | 12.04B | |||
Interest Expense | - | -965K | -776K | -552K | -292K | |||
Income Tax Expense | 215M | 243M | -143M | -34.09M | 15.72M | |||
CAPEX | -582M | -692M | -983M | -553M | -441M | |||
EBT | 1.45B | 1.7B | -582M | 306M | 630M | |||
D&A | 158M | 182M | 195M | 219M | 252M | |||
Operating Income | 1.45B | 1.7B | -569M | 315M | 632M | |||
Net Income | 1.23B | 1.45B | -440M | 340M | 615M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
China | 3.27B | 3.36B | 1.44B | 2.18B | 2.52B | |||
International | 92.81M | 256M | 276M | 426M | 528M | |||
Mainland China | - | - | - | - | - |
- Stock Market
- Equities
- 603087 Stock
- Financials Gan & Lee Pharmaceuticals.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition